Aktis Oncology AKTS Institutional Ownership

Updated Oct 10, 2026

Aktis Oncology, Inc. (NASDAQ:AKTS) appeared in the 13F filings of 115 institutional investors for the quarter ended June 30, 2026.

• These investors held 61.80% of outstanding shares in Q2 2026, down from 65.00% the quarter before.
• Shares of AKTS held in total fell 1.55% from Q1 2026.
• Of the 115 holders of AKTS in Q2 2026, 82 added to their positions, 17 reduced their stakes and 16 left their positions unchanged.
• Combined, institutional investors held 34.17Mn shares of AKTS as of Q2 2026, down 538.54K from the prior quarter.
• MPM BioImpact LLC was the top holder of Aktis Oncology as of June 30, 2026, with 4.84Mn shares, or 8.74% of shares outstanding.
• The largest position increases in AKTS for Q2 2026 were by BlackRock, Inc. (+166.23K shares), Barclays PLC (+141.97K shares), State Street Corp (+55.76K shares), Morgan Stanley (+31.91K shares) and Northern Trust Corp (+31.1K shares).
• Holders that trimmed the most shares of Aktis Oncology in Q2 2026 while keeping a position were T. Rowe Price Associates Inc (-800.7K shares), Wellington Management Group LLP (-350.8K shares), UBS Group AG (-253.3K shares), Ra Capital Management, L.P. (-188.68K shares) and FMR LLC (-100.75K shares).
• Per Business Quant, the top 10 investors in AKTS for the quarter ended June 30, 2026 were MPM BioImpact LLC (4.84Mn shares), EcoR1 Capital, LLC (4.82Mn shares), Blue Owl Capital Holdings LP (3.07Mn shares), BlackRock, Inc. (2.28Mn shares), T. Rowe Price Investment Management, Inc. (2.05Mn shares), Wellington Management Group LLP (1.97Mn shares), RTW Investments, LP (1.59Mn shares), Ra Capital Management, L.P. (1.31Mn shares), Jupiter Topco LLC (1.31Mn shares) and Baker Bros. Advisors LP (996.35K shares).